Public/private partnership improves UK's clinical research competitiveness

20 January 2011

A new report shows that collaboration between the UK’s life sciences industry, the National Health Service (NHS) and the National Institute for Health Research (NIHR) Clinical Research Network is enhancing the country’s clinical research competitiveness.

The NIHR Clinical Research Network North West Exemplar Programme (NWEP) - supported by the NHS North West Strategic Health Authority, NHS chief executives and senior industry leaders - was initiated to demonstrate that the NHS could compete with Europe in the set-up and delivery of high quality, commercially-sponsored clinical research studies.

The NWEP Phase II Report shows that the 20 participating studies achieved a median set-up time of 54 days, which matches the best performance levels in Europe. Seven of the 20 studies recruited the first patient in the world, a key indicator of efficient study set-up and strong evidence that the Clinical Research Network is succeeding in streamlining research governance. Additionally, 18 of the 20 studies are on course to meet, or exceed, their patient recruitment target.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical